Nebivolol

Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients of >70 years.

BYSTOLIC® (nebivolol tablets) is indicated for:  The treatment of mild to moderate essential hypertension. BYSTOLIC may be used alone or concomitantly with thiazide diuretics or angiotensin converting enzyme (ACE) inhibitors. 2 Recommended Dose and Dosage Adjustment and 14 CLINICAL TRIALS.

BYSTOLIC is not recommended for the emergency treatment of hypertensive crises. 1 Pediatrics The safety and efficacy of BYSTOLIC in pediatric patients have not been established and therefore use in children is not recommended. 2 Geriatrics No dosage adjustment is required in geriatric patients.

Of the total number of patients receiving BYSTOLIC in clinical studies, 436 (18%) were 65 years of age or older. No differences in efficacy or safety of BYSTOLIC were observed between older and younger patients. 3 Pharmacokinetics.

1 INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. 1 ) ]. Nebivolol may be used alone or in combination with other antihypertensive agents [ see Drug Interactions ( 7 )].

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs.

There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).